Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer
•Colon cancer in one of the main health-related problems which is incurable particularly in advanced stages.•Prostanoids and particularly prostaglandin E2 (PGE2) are important inflammatory lipid mediators.•PGE2 plays an important role in tumorigenesis process of colon cancer.•PGE2 can be considered...
Uloženo v:
| Vydáno v: | Prostaglandins & other lipid mediators Ročník 144; s. 106338 |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Elsevier Inc
01.10.2019
|
| Témata: | |
| ISSN: | 1098-8823 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | •Colon cancer in one of the main health-related problems which is incurable particularly in advanced stages.•Prostanoids and particularly prostaglandin E2 (PGE2) are important inflammatory lipid mediators.•PGE2 plays an important role in tumorigenesis process of colon cancer.•PGE2 can be considered as potent therapeutic target for colon cancer therapy.
Although colon cancer is one of the most important triggers of cancer related mortality, a few therapeutic options exist for this disease, including combination chemotherapy, anti-EGFR and anti-angiogenic agents. However, none of these therapeutics are fully effective for complete remission, and this issue needs further investigations, particularly in the patients with advanced disease. It has been shown that colon carcinogenesis process is associated with upregulation of prostaglandin (PG) levels. Moreover, conversion of pre-malignant cells to malignant was also related with increased generation of PGs in susceptible subjects. Among the prostanoids, PGE2 is the most important produced member which generated in high levels by colon tumor cells. Generation of PGE2 by action of cyclooxygenase (COX)-2 can promote growth and development, resistance to apoptosis, proliferation, invasion and metastasis, angiogenesis and drug resistance in colon cancer. Increased levels of PGE2 and COX-2 in colon cancer is reported by various investigators which was associated with disease progression. It is suggested that there is a positive feedback loop between COX-2 and PGE2, in which function of COX-2 induces generation of PGE2, and upregulation of PGE2 increases the expression of COX-2 in colon cancer. Although an existence of this feedback loop is well-documented, its precise mechanism, signaling pathways, and the particular E-type prostanoid (EP) receptor mediating this feedback are elusive. Therefore, it seems that targeting COX-2/PGE2/EP receptors may be supposed as a potent therapeutic strategy for treatment of colon cancer. In this review, we try to clarify the role of PGE2 in cancer progression and its targeting for treatment of colon cancer. |
|---|---|
| AbstractList | Although colon cancer is one of the most important triggers of cancer related mortality, a few therapeutic options exist for this disease, including combination chemotherapy, anti-EGFR and anti-angiogenic agents. However, none of these therapeutics are fully effective for complete remission, and this issue needs further investigations, particularly in the patients with advanced disease. It has been shown that colon carcinogenesis process is associated with upregulation of prostaglandin (PG) levels. Moreover, conversion of pre-malignant cells to malignant was also related with increased generation of PGs in susceptible subjects. Among the prostanoids, PGE2 is the most important produced member which generated in high levels by colon tumor cells. Generation of PGE2 by action of cyclooxygenase (COX)-2 can promote growth and development, resistance to apoptosis, proliferation, invasion and metastasis, angiogenesis and drug resistance in colon cancer. Increased levels of PGE2 and COX-2 in colon cancer is reported by various investigators which was associated with disease progression. It is suggested that there is a positive feedback loop between COX-2 and PGE2, in which function of COX-2 induces generation of PGE2, and upregulation of PGE2 increases the expression of COX-2 in colon cancer. Although an existence of this feedback loop is well-documented, its precise mechanism, signaling pathways, and the particular E-type prostanoid (EP) receptor mediating this feedback are elusive. Therefore, it seems that targeting COX-2/PGE2/EP receptors may be supposed as a potent therapeutic strategy for treatment of colon cancer. In this review, we try to clarify the role of PGE2 in cancer progression and its targeting for treatment of colon cancer.Although colon cancer is one of the most important triggers of cancer related mortality, a few therapeutic options exist for this disease, including combination chemotherapy, anti-EGFR and anti-angiogenic agents. However, none of these therapeutics are fully effective for complete remission, and this issue needs further investigations, particularly in the patients with advanced disease. It has been shown that colon carcinogenesis process is associated with upregulation of prostaglandin (PG) levels. Moreover, conversion of pre-malignant cells to malignant was also related with increased generation of PGs in susceptible subjects. Among the prostanoids, PGE2 is the most important produced member which generated in high levels by colon tumor cells. Generation of PGE2 by action of cyclooxygenase (COX)-2 can promote growth and development, resistance to apoptosis, proliferation, invasion and metastasis, angiogenesis and drug resistance in colon cancer. Increased levels of PGE2 and COX-2 in colon cancer is reported by various investigators which was associated with disease progression. It is suggested that there is a positive feedback loop between COX-2 and PGE2, in which function of COX-2 induces generation of PGE2, and upregulation of PGE2 increases the expression of COX-2 in colon cancer. Although an existence of this feedback loop is well-documented, its precise mechanism, signaling pathways, and the particular E-type prostanoid (EP) receptor mediating this feedback are elusive. Therefore, it seems that targeting COX-2/PGE2/EP receptors may be supposed as a potent therapeutic strategy for treatment of colon cancer. In this review, we try to clarify the role of PGE2 in cancer progression and its targeting for treatment of colon cancer. Although colon cancer is one of the most important triggers of cancer related mortality, a few therapeutic options exist for this disease, including combination chemotherapy, anti-EGFR and anti-angiogenic agents. However, none of these therapeutics are fully effective for complete remission, and this issue needs further investigations, particularly in the patients with advanced disease. It has been shown that colon carcinogenesis process is associated with upregulation of prostaglandin (PG) levels. Moreover, conversion of pre-malignant cells to malignant was also related with increased generation of PGs in susceptible subjects. Among the prostanoids, PGE2 is the most important produced member which generated in high levels by colon tumor cells. Generation of PGE2 by action of cyclooxygenase (COX)-2 can promote growth and development, resistance to apoptosis, proliferation, invasion and metastasis, angiogenesis and drug resistance in colon cancer. Increased levels of PGE2 and COX-2 in colon cancer is reported by various investigators which was associated with disease progression. It is suggested that there is a positive feedback loop between COX-2 and PGE2, in which function of COX-2 induces generation of PGE2, and upregulation of PGE2 increases the expression of COX-2 in colon cancer. Although an existence of this feedback loop is well-documented, its precise mechanism, signaling pathways, and the particular E-type prostanoid (EP) receptor mediating this feedback are elusive. Therefore, it seems that targeting COX-2/PGE2/EP receptors may be supposed as a potent therapeutic strategy for treatment of colon cancer. In this review, we try to clarify the role of PGE2 in cancer progression and its targeting for treatment of colon cancer. •Colon cancer in one of the main health-related problems which is incurable particularly in advanced stages.•Prostanoids and particularly prostaglandin E2 (PGE2) are important inflammatory lipid mediators.•PGE2 plays an important role in tumorigenesis process of colon cancer.•PGE2 can be considered as potent therapeutic target for colon cancer therapy. Although colon cancer is one of the most important triggers of cancer related mortality, a few therapeutic options exist for this disease, including combination chemotherapy, anti-EGFR and anti-angiogenic agents. However, none of these therapeutics are fully effective for complete remission, and this issue needs further investigations, particularly in the patients with advanced disease. It has been shown that colon carcinogenesis process is associated with upregulation of prostaglandin (PG) levels. Moreover, conversion of pre-malignant cells to malignant was also related with increased generation of PGs in susceptible subjects. Among the prostanoids, PGE2 is the most important produced member which generated in high levels by colon tumor cells. Generation of PGE2 by action of cyclooxygenase (COX)-2 can promote growth and development, resistance to apoptosis, proliferation, invasion and metastasis, angiogenesis and drug resistance in colon cancer. Increased levels of PGE2 and COX-2 in colon cancer is reported by various investigators which was associated with disease progression. It is suggested that there is a positive feedback loop between COX-2 and PGE2, in which function of COX-2 induces generation of PGE2, and upregulation of PGE2 increases the expression of COX-2 in colon cancer. Although an existence of this feedback loop is well-documented, its precise mechanism, signaling pathways, and the particular E-type prostanoid (EP) receptor mediating this feedback are elusive. Therefore, it seems that targeting COX-2/PGE2/EP receptors may be supposed as a potent therapeutic strategy for treatment of colon cancer. In this review, we try to clarify the role of PGE2 in cancer progression and its targeting for treatment of colon cancer. |
| ArticleNumber | 106338 |
| Author | Sabz, Gholamabas Jadidi-Niaragh, Farhad Karpisheh, Vahid Namdar, Afshin Yousefi, Mehdi Hojjat-Farsangi, Mohammad Yousefi, Bahman Azizi, Gholamreza Nikkhoo, Afshin Ghalamfarsa, Ghasem |
| Author_xml | – sequence: 1 givenname: Vahid surname: Karpisheh fullname: Karpisheh, Vahid organization: Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran – sequence: 2 givenname: Afshin surname: Nikkhoo fullname: Nikkhoo, Afshin organization: Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran – sequence: 3 givenname: Mohammad surname: Hojjat-Farsangi fullname: Hojjat-Farsangi, Mohammad organization: Bioclinicum, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden – sequence: 4 givenname: Afshin surname: Namdar fullname: Namdar, Afshin organization: Department of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, T6G 2E1 Canada – sequence: 5 givenname: Gholamreza surname: Azizi fullname: Azizi, Gholamreza organization: Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran – sequence: 6 givenname: Ghasem surname: Ghalamfarsa fullname: Ghalamfarsa, Ghasem organization: Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran – sequence: 7 givenname: Gholamabas surname: Sabz fullname: Sabz, Gholamabas organization: Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran – sequence: 8 givenname: Mehdi surname: Yousefi fullname: Yousefi, Mehdi organization: Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran – sequence: 9 givenname: Bahman surname: Yousefi fullname: Yousefi, Bahman organization: Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran – sequence: 10 givenname: Farhad surname: Jadidi-Niaragh fullname: Jadidi-Niaragh, Farhad email: jadidif@tbzmed.ac.ir organization: Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31100474$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:142251617$$DView record from Swedish Publication Index (Karolinska Institutet) |
| BookMark | eNqNkT9PwzAQxT2AgAJfAXlgYEnxn7R2JBaoKCAVwQCz5TgXcEnjYDsgvj2uUhAwMZ1197un83sjtNW6FhA6pmRMCZ2eLseddyHqp0a3lW3DmBFapNGUc7mF9igpZCYl47toFMKSkDSmZAft8lRILvI9dHv_UwBfMqwD1rhzEdqI4zN43UEfrcFR-yeIuHYeRw86rtaAq7FxjWux0a0Bf4C2a90EONzUffQ4v3yYXWeLu6ub2fkiM3lBYkbFVFeFSCfkojbTshSy1kxKaSSkLuXc5IJDIYpqUk5oxSiraalpbRibkAr4PsoG3fAOXV-qztuV9h_Kaas2rZf0ApWLQuR54k8GPtn12kOIamWDgSb9GlwfFGOcES5FwRN6tEH7cgXVt_SXZQk4GwCTnAse6m-EErVORS3V71TUOhU1pJLWL_6sGxt1tK6NXtvmvyLzQQSSyW8WvArGQkqgsh5MVJWz_xP6BOHMtu0 |
| CitedBy_id | crossref_primary_10_1016_j_canlet_2020_10_021 crossref_primary_10_1016_j_ejmech_2025_117919 crossref_primary_10_3390_cancers14143333 crossref_primary_10_3390_cells14130987 crossref_primary_10_1016_j_fct_2022_113062 crossref_primary_10_3390_antiox13020220 crossref_primary_10_1097_MD_0000000000033302 crossref_primary_10_1155_2022_5220368 crossref_primary_10_1016_j_phymed_2023_155131 crossref_primary_10_1038_s41598_023_48073_w crossref_primary_10_3390_biomedicines10112763 crossref_primary_10_3389_fphar_2021_709324 crossref_primary_10_1371_journal_ppat_1008508 crossref_primary_10_3390_ijms222413311 crossref_primary_10_1038_s41392_020_00443_w crossref_primary_10_3390_ijms231810225 crossref_primary_10_7759_cureus_70312 crossref_primary_10_1016_j_jddst_2021_102532 crossref_primary_10_1007_s12010_022_04131_z crossref_primary_10_3390_ijms242316947 crossref_primary_10_3389_fphar_2022_1014508 crossref_primary_10_1177_15330338231212073 crossref_primary_10_1186_s12943_024_02208_3 crossref_primary_10_3390_ijms21207680 crossref_primary_10_3390_md18120593 crossref_primary_10_3748_wjg_v28_i26_3027 crossref_primary_10_3390_biology9120434 crossref_primary_10_1186_s12885_025_14715_7 crossref_primary_10_3389_fonc_2022_850767 crossref_primary_10_1038_s12276_021_00555_5 crossref_primary_10_1371_journal_pone_0251942 crossref_primary_10_1016_j_biocel_2024_106599 crossref_primary_10_1016_j_bcp_2024_116259 crossref_primary_10_1016_j_ejphar_2021_174173 crossref_primary_10_1007_s10311_023_01668_1 crossref_primary_10_1002_cbf_4133 crossref_primary_10_1007_s10616_024_00692_5 crossref_primary_10_1080_08820139_2025_2529970 crossref_primary_10_1155_2023_3781091 crossref_primary_10_3390_cancers14153714 crossref_primary_10_3892_ijo_2020_4983 crossref_primary_10_3390_ijms22115813 crossref_primary_10_3389_fmicb_2022_988734 crossref_primary_10_1016_j_lfs_2021_119132 crossref_primary_10_1007_s43440_024_00569_6 crossref_primary_10_1016_j_ijpharm_2022_122462 crossref_primary_10_3390_cancers14184429 crossref_primary_10_3389_fphar_2020_00533 crossref_primary_10_3390_ph16101392 crossref_primary_10_3389_fonc_2021_811486 crossref_primary_10_3390_cancers14102563 crossref_primary_10_1186_s12935_022_02528_8 crossref_primary_10_1016_j_molstruc_2023_137323 crossref_primary_10_3389_fphar_2024_1418560 crossref_primary_10_1016_j_intimp_2019_106087 crossref_primary_10_1177_1934578X231194808 crossref_primary_10_3390_biology11040590 crossref_primary_10_1016_j_ejmech_2023_115566 crossref_primary_10_1016_j_jff_2023_105427 crossref_primary_10_1002_ame2_12476 crossref_primary_10_1007_s00210_024_03482_0 crossref_primary_10_1186_s12866_023_03152_w crossref_primary_10_1002_mnfr_202000463 crossref_primary_10_1124_pharmrev_123_000901 crossref_primary_10_1016_j_prp_2020_153247 crossref_primary_10_1016_j_ejphar_2021_173989 crossref_primary_10_1016_j_jbior_2019_100653 crossref_primary_10_1089_omi_2022_0185 crossref_primary_10_1016_j_amepre_2020_04_023 crossref_primary_10_1016_j_fbio_2024_104371 crossref_primary_10_3390_antiox13030284 crossref_primary_10_1038_s41401_023_01158_8 crossref_primary_10_3892_etm_2025_12945 crossref_primary_10_3389_fphar_2022_1032806 crossref_primary_10_15421_0225032 crossref_primary_10_3390_ijms23010225 crossref_primary_10_1007_s00432_024_05755_w crossref_primary_10_1007_s10753_021_01485_0 crossref_primary_10_1111_ijd_17711 crossref_primary_10_3390_nu12010103 |
| Cites_doi | 10.1158/0008-5472.CAN-06-2105 10.1093/carcin/bgp014 10.1016/j.ejphar.2015.10.044 10.1159/000086629 10.1189/jlb.0405226 10.1016/j.biochi.2010.02.006 10.1016/j.canlet.2012.02.003 10.1080/14728222.2019.1559829 10.1074/jbc.R600038200 10.1182/blood-2009-12-258038 10.1186/1423-0127-18-88 10.1056/NEJMoa050493 10.1038/sj.bjc.6690033 10.1038/nm0302-289 10.1038/nbt1137 10.2174/1568009615666150216170008 10.1016/j.soc.2017.11.001 10.1002/jcp.25873 10.1074/jbc.M302474200 10.1016/j.jconrel.2016.12.012 10.1038/nm0901-1048 10.1146/annurev.med.57.121304.131253 10.1097/SLE.0000000000000050 10.1007/s13277-013-0743-x 10.1146/annurev-pathol-011110-130235 10.1146/annurev.biochem.69.1.145 10.1124/jpet.110.173278 10.1111/j.1753-4887.2011.00439.x 10.1080/01635581.2016.1213866 10.4049/jimmunol.175.3.1483 10.1002/cncr.24760 10.1136/gut.2010.233718 10.3109/14397595.2013.854056 10.1158/0008-5472.CAN-06-2067 10.1016/j.yexcr.2007.06.004 10.1038/nrc2645 10.1007/s10555-007-9096-5 10.1084/jem.20052124 10.1056/NEJMoa050405 10.1007/s00262-016-1879-5 10.1046/j.1365-2222.1999.00006.x-i2 10.3109/21691401.2014.953633 10.1073/pnas.94.7.3336 10.1056/NEJMra0804588 10.1056/NEJM200006293422603 10.1093/jnci/90.21.1609 10.18632/oncotarget.5403 10.1021/pr501236y 10.4049/jimmunol.178.7.4097 10.1111/j.1399-0004.2009.01230.x 10.1038/nm.3175 10.1016/S0304-3835(00)00339-6 10.1038/nature11252 10.1111/j.1582-4934.2007.00032.x 10.4049/jimmunol.161.7.3746 10.1016/j.ejphar.2013.08.002 10.1172/JCI119400 10.1186/1748-5908-8-58 10.1186/1423-0127-18-61 10.4049/jimmunol.165.8.4298 10.1074/jbc.M009689200 10.1054/bjoc.2000.1270 10.1007/s12262-013-0882-8 10.1007/s13277-013-0832-x 10.1074/jbc.M413056200 10.3390/ijms18061132 10.1016/j.biocel.2009.09.015 10.1056/NEJMra012242 10.3109/08923970903283662 10.1158/1078-0432.CCR-09-0788 10.1186/s11671-016-1520-8 10.1002/jcb.23247 10.1002/ijc.1397 10.1158/2159-8290.CD-13-0315 10.4161/cbt.10.10.13373 10.4049/jimmunol.181.1.721 10.3109/08923971003667627 10.3233/JBR-170159 10.1126/science.1116221 10.1016/S1535-6108(03)00310-6 10.1080/00914037.2016.1180610 10.2174/138161206777698972 10.3748/wjg.v23.i7.1171 10.1038/sj.bjc.6604490 10.1038/onc.2009.421 10.1042/BSR20140078 10.1182/blood-2011-07-365825 10.1038/nrc1739 10.3109/21691401.2014.955107 10.1021/cr2002992 10.1016/S0959-8049(11)70183-6 10.1126/science.8484121 10.1007/s11010-010-0469-7 10.1016/j.biopha.2018.09.177 10.1038/436792a 10.1038/nrg2574 10.1007/s13277-015-4004-z 10.1038/35094017 10.1016/0016-5085(94)90246-1 10.1016/j.jss.2003.11.010 |
| ContentType | Journal Article |
| Copyright | 2019 Elsevier Inc. Copyright © 2019 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2019 Elsevier Inc. – notice: Copyright © 2019 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTPV AOWAS |
| DOI | 10.1016/j.prostaglandins.2019.106338 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic SwePub SwePub Articles |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| ExternalDocumentID | oai_swepub_ki_se_479744 31100474 10_1016_j_prostaglandins_2019_106338 S1098882319300279 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M .GJ .~1 0R~ 123 1B1 1RT 1~. 1~5 29P 3O- 4.4 457 4G. 53G 5VS 7-5 71M 8P~ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABFRF ABGSF ABMAC ABOCM ABUDA ABXDB ABYKQ ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC DOVZS DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FGOYB FIRID FNPLU FYGXN GBLVA HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SES SEW SPCBC SSU SSZ T5K UHS UNMZH ZGI ZXP ~G- ~KM 9DU AATTM AAXKI AAYWO AAYXX ABJNI ABWVN ACLOT ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGQPQ AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION EFKBS ~HD BNPGV CGR CUY CVF ECM EIF NPM SSH 7X8 ADTPV AOWAS |
| ID | FETCH-LOGICAL-c490t-176ad9700447fc6bb78fa2888c8e700133c473e979d5b51d212f1ba1fc2250de3 |
| ISICitedReferencesCount | 98 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000494887500013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1098-8823 |
| IngestDate | Tue Nov 25 03:32:42 EST 2025 Wed Oct 01 14:18:56 EDT 2025 Thu Apr 03 07:08:08 EDT 2025 Sat Nov 29 07:01:01 EST 2025 Tue Nov 18 20:35:43 EST 2025 Fri Feb 23 02:27:22 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | E-type prostanoid receptor Prostaglandin E2 Colon cancer Cyclooxygenase-2 |
| Language | English |
| License | Copyright © 2019 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c490t-176ad9700447fc6bb78fa2888c8e700133c473e979d5b51d212f1ba1fc2250de3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 31100474 |
| PQID | 2232038793 |
| PQPubID | 23479 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_479744 proquest_miscellaneous_2232038793 pubmed_primary_31100474 crossref_primary_10_1016_j_prostaglandins_2019_106338 crossref_citationtrail_10_1016_j_prostaglandins_2019_106338 elsevier_sciencedirect_doi_10_1016_j_prostaglandins_2019_106338 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-10-01 |
| PublicationDateYYYYMMDD | 2019-10-01 |
| PublicationDate_xml | – month: 10 year: 2019 text: 2019-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Prostaglandins & other lipid mediators |
| PublicationTitleAlternate | Prostaglandins Other Lipid Mediat |
| PublicationYear | 2019 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Walther, Johnstone, Swanton, Midgley, Tomlinson, Kerr (bib0025) 2009; 9 Kazemi, Raoofi Mohseni, Hojjat-Farsangi, Anvari, Ghalamfarsa, Mohammadi (bib0030) 2018; 233 Sheng, Shao, Washington, DuBois (bib0320) 2001; 276 Smith, Urade, Jakobsson (bib0145) 2011; 111 Sheng, Shao, Kirkland, Isakson, Coffey, Morrow (bib0315) 1997; 99 Nakanishi, Gokhale, Meuillet, Rosenberg (bib0350) 2010; 92 Sano, Kawahito, Wilder, Hashiramoto, Mukai, Asai (bib0085) 1995; 55 Solomon, McMurray, Pfeffer, Wittes, Fowler, Finn (bib0450) 2005; 352 Nadri, Mahmoudvand, Ahmadinejad, Farrokhfar, Obeidavi (bib0235) 2016; 4 Baratelli, Lin, Zhu, Yang, Heuzé-Vourc’h, Zeng (bib0420) 2005; 175 Beiranvand, Eatemadi, Karimi (bib0195) 2016; 11 Masjedi, Hashemi, Hojjat-Farsangi, Ghalamfarsa, Azizi, Yousefi (bib0035) 2018; 108 Kundu, Yang, Dorsey, Fulton (bib0360) 2001; 93 McLeod, Murray (bib0240) 1999; 79 Vladoiu, Labrie, Létourneau, Egesborg, Gagné, Billard (bib0290) 2015; 6 Hsu, Lin, Shen, Shibu, Li, Chang (bib0575) 2017; 18 Faber, Coffee, Costa, Dastur, Ebi, Hata (bib0210) 2014; 4 Shao, Sheng (bib0475) 2007; 178 Mirshafiey, Jadidi-Niaragh (bib0340) 2010; 32 Hsu, Hu, Lin, Kuo, Chen, Chen (bib0555) 2011; 18 Cherukuri, Chen, Goulet, Young, Han, Heimark (bib0530) 2007; 313 Li, Zhang, An, Zhang, Song, Wang (bib0525) 2015; 14 Ghalamfarsa, Kazemi, Raoofi Mohseni, Masjedi, Hojjat-Farsangi, Yousefi (bib0045) 2019 Sadanandam, Lyssiotis, Homicsko, Collisson, Gibb, Wullschleger (bib0250) 2013; 19 Aiyelabegan, Zaidi, Fanuel, Eatemadi, Ebadi, Sadroddiny (bib0190) 2016; 65 Fukuda, Kelly, Semenza (bib0100) 2003; 63 Tenesa, Dunlop (bib0225) 2009; 10 Smith, DeWitt, Garavito (bib0465) 2000; 69 Legler, Bruckner, Uetz-von Allmen, Krause (bib0380) 2010; 42 Jadidi-Niaragh, Ghalamfarsa, Yousefi, Tabrizi, Shokri (bib0055) 2013; 34 Park, Kim, Choi, Jeong, Heo, Kim (bib0070) 2011; 336 Lynch, Lynch, Lanspa, Snyder, Lynch, Boland (bib0230) 2009; 76 Mirshafiey, Jadidi-Niaragh (bib0435) 2010; 32 Daraee, Eatemadi, Abbasi, Fekri Aval, Kouhi, Akbarzadeh (bib0200) 2016; 44 Greenhough, Smartt, Moore, Roberts, Williams, Paraskeva (bib0370) 2009; 30 Liu, Reinmuth, Stoeltzing, Parikh, Tellez, Williams (bib0470) 2003; 63 Pan, Skaer, Yu, Zhao, Ren, Oshima (bib0175) 2017; 7 Dannenberg, Subbaramaiah (bib0385) 2003; 4 Buchanan, Wang, Bargiacchi, DuBois (bib0325) 2003; 278 Pai, Soreghan, Szabo, Pavelka, Baatar, Tarnawski (bib0305) 2002; 8 Mutoh, Takahashi, Wakabayashi (bib0300) 2006; 12 Watanabe, Kawamori, Nakatsugi, Ohta, Ohuchida, Yamamoto (bib0125) 1999; 59 Sidahmed, Sen, Ren, Patel, Turgeon, Ruffin (bib0585) 2016; 68 Chandramouli, Mercado-Pimentel, Hutchinson, Gibadulinová, Olson, Dickinson (bib0485) 2010; 10 Muthuswamy, Mueller-Berghaus, Haberkorn, Reinhart, Schadendorf, Kalinski (bib0505) 2010 Aaltonen, Peltomaki, Leach, Sistonen, Pylkkanen, Mecklin (bib0180) 1993; 260 Sugimoto, Narumiya (bib0375) 2007; 282 Yousefi, Jadidi-Niaragh, Azizi, Hajighasemi, Mirshafiey (bib0335) 2014; 24 Eberhart, Coffey, Radhika, Giardiello, Ferrenbach, DuBois (bib0080) 1994; 107 Wang, DuBois (bib0155) 2010; 29 Yoshida, Fujino, Otake, Seira, Regan, Murayama (bib0490) 2013; 718 Pai, Soreghan, Szabo, Pavelka, Baatar, Tarnawski (bib0595) 2002; 8 Tsai, Wu, Shyu, Wang, Jiang (bib0560) 2011; 18 Kapsenberg, Hilkens, Wierenga, Kalinski (bib0415) 1999; 29 Yazdani, Mohammadnia-Afrouzi, Yousefi, Anvari, Ghalamfarsa, Hasannia (bib0060) 2015; 36 Edwards, Ward, Kohler, Eheman, Zauber, Anderson (bib0215) 2010; 116 Gupta, DuBois (bib0260) 2001; 1 Sonoshita, Takaku, Sasaki, Sugimoto, Ushikubi, Narumiya (bib0115) 2001; 7 Park, Kim, Choi, Jeong, Heo, Kim (bib0540) 2011; 336 Shao, Lee, Guo, Evers, Sheng (bib0310) 2003; 63 Voutsadakis (bib0365) 2007; 11 Hsu, Chen, Day, Lin, Li, Tu (bib0580) 2017; 23 Jonuleit, Kühn, Müller, Steinbrink, Paragnik, Schmitt (bib0395) 1997; 2 James, Richardson, Wang, Proctor, Colditz (bib0285) 2013; 8 Yoshimatsu, Golijanin, Paty, Soslow, Jakobsson, DeLellis (bib0160) 2001; 7 Orlando, Pilone, Vitiello, Gervasi, Lerose, Silecchia (bib0165) 2014; 24 Adams, Weiner (bib0280) 2005; 23 Ludwig, Weinstein (bib0245) 2005; 5 Whittaker, Bahjat, Moldawer, Clare-Salzler (bib0410) 2000; 165 Wu (bib0020) 2018; 27 Tavolari, Munarini, Storci, Laufer, Chieco, Guarnieri (bib0445) 2012; 321 Siegel, Ma, Zou, Jemal (bib0010) 2014; 64 Tomozawa, Tsuno, Sunami, Hatano, Kitayama, Osada (bib0110) 2000; 83 Backlund, Mann, Dubois (bib0075) 2005; 69 Ries, Harkins, Krapcho, Mariotto, Miller, Feuer (bib0170) 2006 Fulton, Ma, Kundu (bib0390) 2006; 66 Khayrullina, Yen, Jing, Ganea (bib0425) 2008; 181 Ahmadinejad, Aliepour, Anbari, Kaviani, Ganjizadeh, Nadri (bib0565) 2015; 77 Cockbain, Toogood, Hull (bib0295) 2012; 61 Tsujii, Kawano, DuBois (bib0330) 1997; 94 Djuric (bib0135) 2011; 69 Nakayama, Mutsuga, Yao, Tosato (bib0400) 2006; 79 Shao, Jung, Liu, Sheng (bib0495) 2005; 280 Yefi, Ponce, Niechi, Silva, Cabello, Rodriguez (bib0535) 2011; 112 Ghalamfarsa, Hadinia, Yousefi, Jadidi-Niaragh (bib0065) 2013; 34 Liu, Lai, Lo (bib0515) 2004; 117 Markowitz, Bertagnolli (bib0015) 2009; 361 Fearon (bib0220) 2011; 6 Lai, Chen, Lin, Tzang, Lin, Tsai (bib0550) 2010; 342 Parsons, Wang, Samuels, Bardelli, Cummins, DeLong (bib0185) 2005; 436 Stein, Atanackovic, Bokemeyer (bib0265) 2011; 47 Balansky, Ganchev, Iltcheva, Nikolov, La Maestra, T Micale (bib0440) 2015; 15 Fujino, Seira, Kurata, Araki, Nakamura, Regan (bib0570) 2015; 768 Taketo (bib0130) 1998; 90 Network (bib0005) 2012; 487 Castellone, Teramoto, Williams, Druey, Gutkind (bib0095) 2005; 310 Wang, Wang, Brown, Daikoku, Ning, Shi (bib0120) 2006; 203 Daraee, Etemadi, Kouhi, Alimirzalu, Akbarzadeh (bib0205) 2016; 44 Cassano, Gasparre, Susca, Lippe, Guanti (bib0510) 2000; 152 Lynch, De la Chapelle (bib0255) 2003; 348 Sheng, Shao, Washington, DuBois (bib0105) 2001 O’callaghan, Kelly, Shanahan, Houston (bib0500) 2008; 99 Sheng, Shao, Kirkland, Isakson, Coffey, Morrow (bib0090) 1997; 99 Menter, Schilsky, DuBois (bib0345) 2010 Steinbach, Lynch, Phillips, Wallace, Hawk, Gordon (bib0455) 2000; 342 Yu, Chai (bib0275) 2014; 34 Shao, Lee, Guo, Evers, Sheng (bib0520) 2003; 63 Backlund, Mann, DuBois (bib0140) 2005; 69 Cha, DuBois (bib0150) 2007; 58 Kazemi, Younesi, Jadidi-Niaragh, Yousefi (bib0590) 2016; 44 Kheshtchin, Arab, Ajami, Mirzaei, Ashourpour, Mousavi (bib0040) 2016; 65 Tammali, Ramana, Singhal, Awasthi, Srivastava (bib0480) 2006; 66 Wang, Honn, Nie (bib0355) 2007; 26 Jadidi-Niaragh, Atyabi, Rastegari, Kheshtchin, Arab, Hassannia (bib0050) 2017; 246 Siegel, Miller, Jemal (bib0270) 2017; 67 Bresalier, Sandler, Quan, Bolognese, Oxenius, Horgan (bib0460) 2005; 352 Obermajer, Muthuswamy, Lesnock, Edwards, Kalinski (bib0430) 2011 Yu, Chadee (bib0405) 1998; 161 Park, Kim, Choi, Jeong, Heo, Kim (bib0545) 2011; 336 Edwards (10.1016/j.prostaglandins.2019.106338_bib0215) 2010; 116 Baratelli (10.1016/j.prostaglandins.2019.106338_bib0420) 2005; 175 Solomon (10.1016/j.prostaglandins.2019.106338_bib0450) 2005; 352 Aaltonen (10.1016/j.prostaglandins.2019.106338_bib0180) 1993; 260 Aiyelabegan (10.1016/j.prostaglandins.2019.106338_bib0190) 2016; 65 Jonuleit (10.1016/j.prostaglandins.2019.106338_bib0395) 1997; 2 Ghalamfarsa (10.1016/j.prostaglandins.2019.106338_bib0065) 2013; 34 Sheng (10.1016/j.prostaglandins.2019.106338_bib0090) 1997; 99 Castellone (10.1016/j.prostaglandins.2019.106338_bib0095) 2005; 310 Siegel (10.1016/j.prostaglandins.2019.106338_bib0010) 2014; 64 Tenesa (10.1016/j.prostaglandins.2019.106338_bib0225) 2009; 10 Yu (10.1016/j.prostaglandins.2019.106338_bib0275) 2014; 34 Yazdani (10.1016/j.prostaglandins.2019.106338_bib0060) 2015; 36 Beiranvand (10.1016/j.prostaglandins.2019.106338_bib0195) 2016; 11 Balansky (10.1016/j.prostaglandins.2019.106338_bib0440) 2015; 15 Sheng (10.1016/j.prostaglandins.2019.106338_bib0105) 2001 Tammali (10.1016/j.prostaglandins.2019.106338_bib0480) 2006; 66 Fujino (10.1016/j.prostaglandins.2019.106338_bib0570) 2015; 768 Backlund (10.1016/j.prostaglandins.2019.106338_bib0140) 2005; 69 Obermajer (10.1016/j.prostaglandins.2019.106338_bib0430) 2011 Sadanandam (10.1016/j.prostaglandins.2019.106338_bib0250) 2013; 19 Mirshafiey (10.1016/j.prostaglandins.2019.106338_bib0340) 2010; 32 Yoshida (10.1016/j.prostaglandins.2019.106338_bib0490) 2013; 718 James (10.1016/j.prostaglandins.2019.106338_bib0285) 2013; 8 Smith (10.1016/j.prostaglandins.2019.106338_bib0145) 2011; 111 Tsai (10.1016/j.prostaglandins.2019.106338_bib0560) 2011; 18 Sonoshita (10.1016/j.prostaglandins.2019.106338_bib0115) 2001; 7 Steinbach (10.1016/j.prostaglandins.2019.106338_bib0455) 2000; 342 Tomozawa (10.1016/j.prostaglandins.2019.106338_bib0110) 2000; 83 Shao (10.1016/j.prostaglandins.2019.106338_bib0495) 2005; 280 Park (10.1016/j.prostaglandins.2019.106338_bib0545) 2011; 336 Wang (10.1016/j.prostaglandins.2019.106338_bib0155) 2010; 29 McLeod (10.1016/j.prostaglandins.2019.106338_bib0240) 1999; 79 Li (10.1016/j.prostaglandins.2019.106338_bib0525) 2015; 14 Orlando (10.1016/j.prostaglandins.2019.106338_bib0165) 2014; 24 Shao (10.1016/j.prostaglandins.2019.106338_bib0310) 2003; 63 Yu (10.1016/j.prostaglandins.2019.106338_bib0405) 1998; 161 Sheng (10.1016/j.prostaglandins.2019.106338_bib0320) 2001; 276 Watanabe (10.1016/j.prostaglandins.2019.106338_bib0125) 1999; 59 Daraee (10.1016/j.prostaglandins.2019.106338_bib0200) 2016; 44 Hsu (10.1016/j.prostaglandins.2019.106338_bib0580) 2017; 23 Daraee (10.1016/j.prostaglandins.2019.106338_bib0205) 2016; 44 Liu (10.1016/j.prostaglandins.2019.106338_bib0470) 2003; 63 Yefi (10.1016/j.prostaglandins.2019.106338_bib0535) 2011; 112 Markowitz (10.1016/j.prostaglandins.2019.106338_bib0015) 2009; 361 Sheng (10.1016/j.prostaglandins.2019.106338_bib0315) 1997; 99 Shao (10.1016/j.prostaglandins.2019.106338_bib0520) 2003; 63 Smith (10.1016/j.prostaglandins.2019.106338_bib0465) 2000; 69 Park (10.1016/j.prostaglandins.2019.106338_bib0540) 2011; 336 Jadidi-Niaragh (10.1016/j.prostaglandins.2019.106338_bib0055) 2013; 34 Kapsenberg (10.1016/j.prostaglandins.2019.106338_bib0415) 1999; 29 Bresalier (10.1016/j.prostaglandins.2019.106338_bib0460) 2005; 352 Hsu (10.1016/j.prostaglandins.2019.106338_bib0575) 2017; 18 Ahmadinejad (10.1016/j.prostaglandins.2019.106338_bib0565) 2015; 77 Masjedi (10.1016/j.prostaglandins.2019.106338_bib0035) 2018; 108 Wang (10.1016/j.prostaglandins.2019.106338_bib0120) 2006; 203 Menter (10.1016/j.prostaglandins.2019.106338_bib0345) 2010 Nakayama (10.1016/j.prostaglandins.2019.106338_bib0400) 2006; 79 Sidahmed (10.1016/j.prostaglandins.2019.106338_bib0585) 2016; 68 Parsons (10.1016/j.prostaglandins.2019.106338_bib0185) 2005; 436 Voutsadakis (10.1016/j.prostaglandins.2019.106338_bib0365) 2007; 11 Kheshtchin (10.1016/j.prostaglandins.2019.106338_bib0040) 2016; 65 Pan (10.1016/j.prostaglandins.2019.106338_bib0175) 2017; 7 Lynch (10.1016/j.prostaglandins.2019.106338_bib0230) 2009; 76 Ghalamfarsa (10.1016/j.prostaglandins.2019.106338_bib0045) 2019 Khayrullina (10.1016/j.prostaglandins.2019.106338_bib0425) 2008; 181 Cherukuri (10.1016/j.prostaglandins.2019.106338_bib0530) 2007; 313 Eberhart (10.1016/j.prostaglandins.2019.106338_bib0080) 1994; 107 Cha (10.1016/j.prostaglandins.2019.106338_bib0150) 2007; 58 Siegel (10.1016/j.prostaglandins.2019.106338_bib0270) 2017; 67 Sugimoto (10.1016/j.prostaglandins.2019.106338_bib0375) 2007; 282 Dannenberg (10.1016/j.prostaglandins.2019.106338_bib0385) 2003; 4 Mutoh (10.1016/j.prostaglandins.2019.106338_bib0300) 2006; 12 Fukuda (10.1016/j.prostaglandins.2019.106338_bib0100) 2003; 63 Kazemi (10.1016/j.prostaglandins.2019.106338_bib0590) 2016; 44 Walther (10.1016/j.prostaglandins.2019.106338_bib0025) 2009; 9 Kundu (10.1016/j.prostaglandins.2019.106338_bib0360) 2001; 93 Adams (10.1016/j.prostaglandins.2019.106338_bib0280) 2005; 23 Whittaker (10.1016/j.prostaglandins.2019.106338_bib0410) 2000; 165 Legler (10.1016/j.prostaglandins.2019.106338_bib0380) 2010; 42 Wu (10.1016/j.prostaglandins.2019.106338_bib0020) 2018; 27 Vladoiu (10.1016/j.prostaglandins.2019.106338_bib0290) 2015; 6 Yousefi (10.1016/j.prostaglandins.2019.106338_bib0335) 2014; 24 Kazemi (10.1016/j.prostaglandins.2019.106338_bib0030) 2018; 233 Mirshafiey (10.1016/j.prostaglandins.2019.106338_bib0435) 2010; 32 Hsu (10.1016/j.prostaglandins.2019.106338_bib0555) 2011; 18 Backlund (10.1016/j.prostaglandins.2019.106338_bib0075) 2005; 69 Ries (10.1016/j.prostaglandins.2019.106338_bib0170) 2006 Muthuswamy (10.1016/j.prostaglandins.2019.106338_bib0505) 2010 Park (10.1016/j.prostaglandins.2019.106338_bib0070) 2011; 336 Taketo (10.1016/j.prostaglandins.2019.106338_bib0130) 1998; 90 Pai (10.1016/j.prostaglandins.2019.106338_bib0305) 2002; 8 Sano (10.1016/j.prostaglandins.2019.106338_bib0085) 1995; 55 Nadri (10.1016/j.prostaglandins.2019.106338_bib0235) 2016; 4 Jadidi-Niaragh (10.1016/j.prostaglandins.2019.106338_bib0050) 2017; 246 Ludwig (10.1016/j.prostaglandins.2019.106338_bib0245) 2005; 5 Lynch (10.1016/j.prostaglandins.2019.106338_bib0255) 2003; 348 Cassano (10.1016/j.prostaglandins.2019.106338_bib0510) 2000; 152 Chandramouli (10.1016/j.prostaglandins.2019.106338_bib0485) 2010; 10 Wang (10.1016/j.prostaglandins.2019.106338_bib0355) 2007; 26 Faber (10.1016/j.prostaglandins.2019.106338_bib0210) 2014; 4 Tavolari (10.1016/j.prostaglandins.2019.106338_bib0445) 2012; 321 Buchanan (10.1016/j.prostaglandins.2019.106338_bib0325) 2003; 278 Greenhough (10.1016/j.prostaglandins.2019.106338_bib0370) 2009; 30 Fulton (10.1016/j.prostaglandins.2019.106338_bib0390) 2006; 66 Yoshimatsu (10.1016/j.prostaglandins.2019.106338_bib0160) 2001; 7 Nakanishi (10.1016/j.prostaglandins.2019.106338_bib0350) 2010; 92 O’callaghan (10.1016/j.prostaglandins.2019.106338_bib0500) 2008; 99 Network (10.1016/j.prostaglandins.2019.106338_bib0005) 2012; 487 Pai (10.1016/j.prostaglandins.2019.106338_bib0595) 2002; 8 Lai (10.1016/j.prostaglandins.2019.106338_bib0550) 2010; 342 Liu (10.1016/j.prostaglandins.2019.106338_bib0515) 2004; 117 Gupta (10.1016/j.prostaglandins.2019.106338_bib0260) 2001; 1 Cockbain (10.1016/j.prostaglandins.2019.106338_bib0295) 2012; 61 Stein (10.1016/j.prostaglandins.2019.106338_bib0265) 2011; 47 Fearon (10.1016/j.prostaglandins.2019.106338_bib0220) 2011; 6 Tsujii (10.1016/j.prostaglandins.2019.106338_bib0330) 1997; 94 Shao (10.1016/j.prostaglandins.2019.106338_bib0475) 2007; 178 Djuric (10.1016/j.prostaglandins.2019.106338_bib0135) 2011; 69 |
| References_xml | – volume: 29 start-page: 33 year: 1999 end-page: 36 ident: bib0415 article-title: The paradigm of type 1 and type 2 antigen‐presenting cells. Implications for atopic allergy publication-title: Clin. Exp. Allergy – volume: 352 start-page: 1071 year: 2005 end-page: 1080 ident: bib0450 article-title: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention publication-title: N. Engl. J. Med. – volume: 18 start-page: 88 year: 2011 ident: bib0560 article-title: Tazarotene-induced gene 1 inhibits prostaglandin E2-stimulated HCT116 colon cancer cell growth publication-title: J. Biomed. Sci. – volume: 4 start-page: 431 year: 2003 end-page: 436 ident: bib0385 article-title: Targeting cyclooxygenase-2 in human neoplasia: rationale and promise publication-title: Cancer Cell – year: 2019 ident: bib0045 article-title: CD73 as a potential opportunity for cancer immunotherapy publication-title: Expert Opin. Ther. Targets – volume: 117 start-page: 223 year: 2004 end-page: 231 ident: bib0515 article-title: Levamisole modulates prostaglandin E2 production and cyclooxygenase II gene expression in human colonic cancer cells1 publication-title: J. Surg. Res. – volume: 280 start-page: 26565 year: 2005 end-page: 26572 ident: bib0495 article-title: Prostaglandin E2 stimulates the β-catenin/T cell factor-dependent transcription in colon cancer publication-title: J. Biol. Chem. – volume: 260 start-page: 812 year: 1993 end-page: 816 ident: bib0180 article-title: Clues to the pathogenesis of familial colorectal cancer publication-title: Science – volume: 161 start-page: 3746 year: 1998 end-page: 3752 ident: bib0405 article-title: Prostaglandin E2 stimulates IL-8 gene expression in human colonic epithelial cells by a posttranscriptional mechanism publication-title: J. Immunol. – volume: 76 start-page: 1 year: 2009 end-page: 18 ident: bib0230 article-title: Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications publication-title: Clin. Genet. – volume: 32 start-page: 543 year: 2010 end-page: 554 ident: bib0435 article-title: Prostaglandins in pathogenesis and treatment of multiple sclerosis publication-title: Immunopharmacol. Immunotoxicol. – year: 2011 ident: bib0430 article-title: Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells towards stable myeloid-derived suppressor cells publication-title: Blood – volume: 67 start-page: 7 year: 2017 end-page: 30 ident: bib0270 article-title: Cancer statistics, 2017 publication-title: CA Cancer J. Clin. – volume: 79 start-page: 95 year: 2006 end-page: 104 ident: bib0400 article-title: Prostaglandin E2 promotes degranulation‐independent release of MCP‐1 from mast cells publication-title: J. Leukoc. Biol. – volume: 8 start-page: 58 year: 2013 ident: bib0285 article-title: Systems intervention to promote colon cancer screening in safety net settings: protocol for a community-based participatory randomized controlled trial publication-title: Implement. Sci. – volume: 718 start-page: 408 year: 2013 end-page: 417 ident: bib0490 article-title: Induction of cyclooxygenase-2 expression by prostaglandin E2 stimulation of the prostanoid EP4 receptor via coupling to Gαi and transactivation of the epidermal growth factor receptor in HCA-7 human colon cancer cells publication-title: Eur. J. Pharmacol. – volume: 278 start-page: 35451 year: 2003 end-page: 35457 ident: bib0325 article-title: Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor publication-title: J. Biol. Chem. – volume: 99 start-page: 502 year: 2008 ident: bib0500 article-title: Prostaglandin E 2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells publication-title: Br. J. Cancer – volume: 90 start-page: 1609 year: 1998 end-page: 1620 ident: bib0130 article-title: Cyclooxygenase-2 inhibitors in tumorigenesis (Part II) publication-title: J. Natl. Cancer Inst. – volume: 321 start-page: 187 year: 2012 end-page: 194 ident: bib0445 article-title: The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells publication-title: Cancer Lett. – volume: 342 start-page: 1946 year: 2000 end-page: 1952 ident: bib0455 article-title: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis publication-title: N. Engl. J. Med. – volume: 65 start-page: 1159 year: 2016 end-page: 1167 ident: bib0040 article-title: Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer publication-title: Cancer Immunol. Immunother. – volume: 47 year: 2011 ident: bib0265 article-title: Current standards and new trends in the primary treatment of colorectal cancer publication-title: Eur. J. Cancer – volume: 4 start-page: 42 year: 2014 end-page: 52 ident: bib0210 article-title: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1 publication-title: Cancer Discov. – year: 2010 ident: bib0505 article-title: PGE2 transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells publication-title: blood – volume: 4 start-page: 202 year: 2016 end-page: 207 ident: bib0235 article-title: Effect of oral Gabapentinon post-operative pain, morphine consumption, nausea and vomiting in patients with urgent appendectomy: a randomized double-blind placebo-controlled trial publication-title: Int. J. Adv. Biol. Biomed. Res. – volume: 42 start-page: 198 year: 2010 end-page: 201 ident: bib0380 article-title: Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances publication-title: Int. J. Biochem. Cell Biol. – volume: 487 start-page: 330 year: 2012 ident: bib0005 article-title: Comprehensive molecular characterization of human colon and rectal cancer publication-title: Nature – volume: 34 start-page: e00161 year: 2014 ident: bib0275 article-title: Lentivirus-mediated knockdown of eukaryotic translation initiation factor 3 subunit D inhibits proliferation of HCT116 colon cancer cells publication-title: Biosci. Rep. – volume: 94 start-page: 3336 year: 1997 end-page: 3340 ident: bib0330 article-title: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential publication-title: Proc. Natl. Acad. Sci. – volume: 10 start-page: 1056 year: 2010 end-page: 1066 ident: bib0485 article-title: The induction of S100p expression by the Prostaglandin E2 (PGE2)/EP4 receptor signaling pathway in colon cancer cells publication-title: Cancer Biol. Ther. – volume: 27 start-page: 235 year: 2018 end-page: 242 ident: bib0020 article-title: Systemic therapy for colon cancer publication-title: Surg. Oncol. Clin. – volume: 63 start-page: 3632 year: 2003 end-page: 3636 ident: bib0470 article-title: Cyclooxygenase-2 is up-regulated by interleukin-1β in human colorectal cancer cells via multiple signaling pathways publication-title: Cancer Res. – volume: 10 start-page: 353 year: 2009 ident: bib0225 article-title: New insights into the aetiology of colorectal cancer from genome-wide association studies publication-title: Nat. Rev. Genet. – volume: 282 start-page: 11613 year: 2007 end-page: 11617 ident: bib0375 article-title: Prostaglandin E receptors publication-title: J. Biol. Chem. – volume: 24 start-page: 225 year: 2014 end-page: 235 ident: bib0335 article-title: The role of leukotrienes in immunopathogenesis of rheumatoid arthritis publication-title: Mod. Rheumatol. – volume: 352 start-page: 1092 year: 2005 end-page: 1102 ident: bib0460 article-title: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial publication-title: N. Engl. J. Med. – volume: 23 start-page: 1147 year: 2005 ident: bib0280 article-title: Monoclonal antibody therapy of cancer publication-title: Nat. Biotechnol. – volume: 178 start-page: 4097 year: 2007 end-page: 4103 ident: bib0475 article-title: Prostaglandin E2 induces the expression of IL-1α in colon cancer cells publication-title: J. Immunol. – volume: 63 start-page: 5218 year: 2003 end-page: 5223 ident: bib0310 article-title: Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin publication-title: Cancer Res. – volume: 44 start-page: 769 year: 2016 end-page: 779 ident: bib0590 article-title: Immunotherapeutic approaches for cancer therapy: an updated review publication-title: Artif. Cells Nanomed. Biotechnol. – volume: 36 start-page: 7339 year: 2015 end-page: 7353 ident: bib0060 article-title: Myeloid-derived suppressor cells in B cell malignancies publication-title: Tumor Biol. – volume: 44 start-page: 410 year: 2016 end-page: 422 ident: bib0200 article-title: Application of gold nanoparticles in biomedical and drug delivery publication-title: Artif. Cells Nanomed. Biotechnol. – volume: 44 start-page: 381 year: 2016 end-page: 391 ident: bib0205 article-title: Application of liposomes in medicine and drug delivery publication-title: Artif. Cells Nanomed. Biotechnol. – volume: 99 start-page: 2254 year: 1997 end-page: 2259 ident: bib0315 article-title: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2 publication-title: J. Clin. Invest. – volume: 64 start-page: 9 year: 2014 end-page: 29 ident: bib0010 article-title: Cancer statistics, 2014 publication-title: CA Cancer J. Clin. – volume: 107 start-page: 1183 year: 1994 end-page: 1188 ident: bib0080 article-title: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas publication-title: Gastroenterology – volume: 112 start-page: 3167 year: 2011 end-page: 3175 ident: bib0535 article-title: Protein kinase CK2 promotes cancer cell viability via up‐regulation of cyclooxygenase‐2 expression and enhanced prostaglandin E2 production publication-title: J. Cell. Biochem. – volume: 1 start-page: 11 year: 2001 ident: bib0260 article-title: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 publication-title: Nat. Rev. Cancer – start-page: 1975 year: 2006 end-page: 2003 ident: bib0170 article-title: SEER Cancer Statistics Review – volume: 15 start-page: 188 year: 2015 end-page: 195 ident: bib0440 article-title: Modulation by licofelone and celecoxib of experimentally induced cancer and preneoplastic lesions in mice exposed to cigarette smoke publication-title: Curr. Cancer Drug Targets – volume: 233 start-page: 2032 year: 2018 end-page: 2057 ident: bib0030 article-title: Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer publication-title: J. Cell. Physiol. – volume: 24 start-page: 400 year: 2014 end-page: 405 ident: bib0165 article-title: Gastric cancer following bariatric surgery: a review publication-title: Surg. Laparosc. Endosc. Percutan. Tech. – volume: 77 start-page: 480 year: 2015 end-page: 483 ident: bib0565 article-title: Fine-needle aspiration, touch imprint, and crush preparation cytology for diagnosing thyroid malignancies in thyroid nodules publication-title: Indian J. Surg. – volume: 108 start-page: 1415 year: 2018 end-page: 1424 ident: bib0035 article-title: The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer publication-title: Biomed. Pharmacother. – volume: 66 start-page: 9705 year: 2006 end-page: 9713 ident: bib0480 article-title: Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells publication-title: Cancer Res. – volume: 65 start-page: 853 year: 2016 end-page: 861 ident: bib0190 article-title: Albumin-based biomaterial for lung tissue engineering applications publication-title: Int. J. Polym. Mater. Polym. Biomater. – volume: 66 start-page: 9794 year: 2006 end-page: 9797 ident: bib0390 article-title: Targeting prostaglandin E EP receptors to inhibit metastasis publication-title: Cancer Res. – volume: 8 start-page: 289 year: 2002 ident: bib0595 article-title: Prostaglandin E 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy publication-title: Nat. Med. – volume: 361 start-page: 2449 year: 2009 end-page: 2460 ident: bib0015 article-title: Molecular basis of colorectal cancer publication-title: N. Engl. J. Med. – volume: 165 start-page: 4298 year: 2000 end-page: 4304 ident: bib0410 article-title: Autoregulation of human monocyte-derived dendritic cell maturation and IL-12 production by cyclooxygenase-2-mediated prostanoid production publication-title: J. Immunol. – volume: 99 start-page: 2254 year: 1997 end-page: 2259 ident: bib0090 article-title: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2 publication-title: J. Clin. Invest. – volume: 203 start-page: 941 year: 2006 end-page: 951 ident: bib0120 article-title: CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer publication-title: J. Exp. Med. – volume: 7 start-page: 147 year: 2017 end-page: 161 ident: bib0175 article-title: Berries and other natural products in pancreatic cancer chemoprevention in human clinical trials publication-title: J. Berry Res. – volume: 93 start-page: 681 year: 2001 end-page: 686 ident: bib0360 article-title: Increased cyclooxygenase‐2 (cox‐2) expression and activity in a murine model of metastatic breast cancer publication-title: Int. J. Cancer – volume: 246 start-page: 46 year: 2017 end-page: 59 ident: bib0050 article-title: CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice publication-title: J. Control. Release – volume: 9 start-page: 489 year: 2009 ident: bib0025 article-title: Genetic prognostic and predictive markers in colorectal cancer publication-title: Nat. Rev. Cancer – volume: 336 start-page: 516 year: 2011 end-page: 523 ident: bib0070 article-title: The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin E2 on the proliferation of colon cancer cells publication-title: J. Pharmacol. Exp. Ther. – volume: 55 start-page: 3785 year: 1995 end-page: 3789 ident: bib0085 article-title: Expression of cyclooxygenase-1 and-2 in human colorectal cancer publication-title: Cancer Res. – volume: 2 start-page: 258 year: 1997 ident: bib0395 article-title: Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under FCS-free conditions: effect of culture conditions on the type of T cell response publication-title: J. Invest. Dermatol. – volume: 14 start-page: 1566 year: 2015 end-page: 1573 ident: bib0525 article-title: Antagonist of prostaglandin E2 receptor 4 induces metabolic alterations in liver of mice publication-title: J. Proteome Res. – volume: 18 start-page: 61 year: 2011 ident: bib0555 article-title: JNK suppression is essential for 17β-Estradiol inhibits prostaglandin E2-Induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells publication-title: J. Biomed. Sci. – volume: 23 start-page: 1171 year: 2017 ident: bib0580 article-title: Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation publication-title: World J. Gastroenterol. – volume: 18 start-page: 1132 year: 2017 ident: bib0575 article-title: Prostaglandin E2-induced COX-2 expressions via EP2 and EP4 signaling pathways in human LoVo colon cancer cells publication-title: Int. J. Mol. Sci. – volume: 12 start-page: 2375 year: 2006 end-page: 2382 ident: bib0300 article-title: Roles of prostanoids in colon carcinogenesis and their potential targeting for cancer chemoprevention publication-title: Curr. Pharm. Des. – volume: 63 start-page: 5218 year: 2003 end-page: 5223 ident: bib0520 article-title: Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin publication-title: Cancer Res. – volume: 69 start-page: 145 year: 2000 end-page: 182 ident: bib0465 article-title: Cyclooxygenases: structural, cellular, and molecular biology publication-title: Ann. Rev. Biochem. – volume: 58 start-page: 239 year: 2007 end-page: 252 ident: bib0150 article-title: NSAIDs and cancer prevention: targets downstream of COX-2 publication-title: Annu. Rev. Med. – volume: 336 start-page: 516 year: 2011 end-page: 523 ident: bib0545 article-title: The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin E2 on the proliferation of colon cancer cells publication-title: J. Pharmacol. Exp. Ther. – volume: 29 start-page: 781 year: 2010 ident: bib0155 article-title: The role of COX-2 in intestinal inflammation and colorectal cancer publication-title: Oncogene – volume: 92 start-page: 660 year: 2010 end-page: 664 ident: bib0350 article-title: mPGES-1 as a target for cancer suppression: a comprehensive invited review “Phospholipase A2 and lipid mediators” publication-title: Biochimie – volume: 336 start-page: 516 year: 2011 end-page: 523 ident: bib0540 article-title: The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin e publication-title: J. Pharmacol. Exp. Ther. – volume: 175 start-page: 1483 year: 2005 end-page: 1490 ident: bib0420 article-title: Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells publication-title: J. Immunol. – volume: 79 start-page: 191 year: 1999 ident: bib0240 article-title: Tumour markers of prognosis in colorectal cancer publication-title: Br. J. Cancer – volume: 30 start-page: 377 year: 2009 end-page: 386 ident: bib0370 article-title: The COX-2/PGE 2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment publication-title: Carcinogenesis – volume: 276 start-page: 18075 year: 2001 end-page: 18081 ident: bib0320 article-title: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells publication-title: J. Biol. Chem. – volume: 34 start-page: 2031 year: 2013 end-page: 2039 ident: bib0055 article-title: Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions publication-title: Tumor Biol. – volume: 111 start-page: 5821 year: 2011 end-page: 5865 ident: bib0145 article-title: Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis publication-title: Chem. Rev. – volume: 19 start-page: 619 year: 2013 ident: bib0250 article-title: A colorectal cancer classification system that associates cellular phenotype and responses to therapy publication-title: Nat. Med. – volume: 61 start-page: 135 year: 2012 end-page: 149 ident: bib0295 article-title: Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer publication-title: Gut – volume: 26 start-page: 525 year: 2007 ident: bib0355 article-title: Cyclooxygenases, prostanoids, and tumor progression publication-title: Cancer Metastasis Rev. – volume: 7 start-page: 3971 year: 2001 end-page: 3976 ident: bib0160 article-title: Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer publication-title: Clin. Cancer Res. – year: 2001 ident: bib0105 article-title: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells publication-title: J. Biol. Chem. – volume: 6 start-page: 40970 year: 2015 ident: bib0290 article-title: Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin publication-title: Oncotarget – volume: 181 start-page: 721 year: 2008 end-page: 735 ident: bib0425 article-title: In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells publication-title: J. Immunol. – volume: 59 start-page: 5093 year: 1999 end-page: 5096 ident: bib0125 article-title: Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis publication-title: Cancer Res. – volume: 436 start-page: 792 year: 2005 ident: bib0185 article-title: Colorectal cancer: mutations in a signalling pathway publication-title: Nature – volume: 83 start-page: 324 year: 2000 ident: bib0110 article-title: Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer publication-title: Br. J. Cancer – volume: 69 start-page: 28 year: 2005 end-page: 32 ident: bib0075 article-title: Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2 publication-title: Oncology – volume: 152 start-page: 217 year: 2000 end-page: 222 ident: bib0510 article-title: Effect of prostaglandin E2 on the proliferation, Ca2+ mobilization and cAMP in HT-29 human colon adenocarcinoma cells publication-title: Cancer Lett. – volume: 7 start-page: 1048 year: 2001 ident: bib0115 article-title: Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc Δ716 knockout mice publication-title: Nat. Med. – volume: 310 start-page: 1504 year: 2005 end-page: 1510 ident: bib0095 article-title: Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-ß-catenin signaling axis publication-title: Science – volume: 768 start-page: 149 year: 2015 end-page: 159 ident: bib0570 article-title: Prostaglandin E2-stimulated prostanoid EP4 receptors induce prolonged de novo prostaglandin E2 synthesis through biphasic phosphorylation of extracellular signal-regulated kinases mediated by activation of protein kinase A in HCA-7 human colon cancer cells publication-title: Eur. J. Pharmacol. – year: 2010 ident: bib0345 article-title: Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward publication-title: Clin. Cancer Res. – volume: 63 start-page: 2330 year: 2003 end-page: 2334 ident: bib0100 article-title: Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1 publication-title: Cancer Res. – volume: 34 start-page: 1349 year: 2013 end-page: 1360 ident: bib0065 article-title: The role of natural killer T cells in B cell malignancies publication-title: Tumor Biol. – volume: 69 start-page: 28 year: 2005 end-page: 32 ident: bib0140 article-title: Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2 publication-title: Oncology – volume: 5 start-page: 845 year: 2005 ident: bib0245 article-title: Biomarkers in cancer staging, prognosis and treatment selection publication-title: Nat. Rev. Cancer – volume: 6 start-page: 479 year: 2011 end-page: 507 ident: bib0220 article-title: Molecular genetics of colorectal cancer publication-title: Annu. Rev. Pathol. Mech. Dis. – volume: 8 start-page: 289 year: 2002 ident: bib0305 article-title: Prostaglandin E 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy publication-title: Nat. Med. – volume: 342 start-page: 63 year: 2010 end-page: 70 ident: bib0550 article-title: 17β-Estradiol inhibits prostaglandin E2-induced COX-2 expressions and cell migration by suppressing Akt and ERK1/2 signaling pathways in human LoVo colon cancer cells publication-title: Mol. Cell. Biochem. – volume: 313 start-page: 2969 year: 2007 end-page: 2979 ident: bib0530 article-title: The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells publication-title: Exp. Cell Res. – volume: 348 start-page: 919 year: 2003 end-page: 932 ident: bib0255 article-title: Hereditary colorectal cancer publication-title: N. Engl. J. Med. – volume: 32 start-page: 219 year: 2010 end-page: 227 ident: bib0340 article-title: Immunopharmacological role of the leukotriene receptor antagonists and inhibitors of leukotrienes generating enzymes in multiple sclerosis publication-title: Immunopharmacol. Immunotoxicol. – volume: 11 start-page: 252 year: 2007 end-page: 285 ident: bib0365 article-title: Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin–proteasome system and Cox‐2 publication-title: J. Cell. Mol. Med. – volume: 116 start-page: 544 year: 2010 end-page: 573 ident: bib0215 article-title: Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates publication-title: Cancer: Interdiscip. Int. J. Am. Cancer Soc. – volume: 69 start-page: 730 year: 2011 end-page: 744 ident: bib0135 article-title: The Mediterranean diet: effects on proteins that mediate fatty acid metabolism in the colon publication-title: Nutr. Rev. – volume: 68 start-page: 1192 year: 2016 end-page: 1201 ident: bib0585 article-title: Colonic saturated fatty acid concentrations and expression of COX-1, but not diet, predict prostaglandin E2 in normal human colon tissue publication-title: Nutr. cancer Biol. – volume: 11 start-page: 307 year: 2016 ident: bib0195 article-title: New updates pertaining to drug delivery of local anesthetics in particular bupivacaine using lipid nanoparticles publication-title: Nanoscale Res. Lett. – volume: 63 start-page: 2330 issue: 9 year: 2003 ident: 10.1016/j.prostaglandins.2019.106338_bib0100 article-title: Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1 publication-title: Cancer Res. – volume: 63 start-page: 5218 issue: 17 year: 2003 ident: 10.1016/j.prostaglandins.2019.106338_bib0310 article-title: Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin publication-title: Cancer Res. – volume: 66 start-page: 9705 issue: 19 year: 2006 ident: 10.1016/j.prostaglandins.2019.106338_bib0480 article-title: Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-06-2105 – volume: 63 start-page: 3632 issue: 13 year: 2003 ident: 10.1016/j.prostaglandins.2019.106338_bib0470 article-title: Cyclooxygenase-2 is up-regulated by interleukin-1β in human colorectal cancer cells via multiple signaling pathways publication-title: Cancer Res. – volume: 30 start-page: 377 issue: 3 year: 2009 ident: 10.1016/j.prostaglandins.2019.106338_bib0370 article-title: The COX-2/PGE 2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment publication-title: Carcinogenesis doi: 10.1093/carcin/bgp014 – volume: 768 start-page: 149 year: 2015 ident: 10.1016/j.prostaglandins.2019.106338_bib0570 article-title: Prostaglandin E2-stimulated prostanoid EP4 receptors induce prolonged de novo prostaglandin E2 synthesis through biphasic phosphorylation of extracellular signal-regulated kinases mediated by activation of protein kinase A in HCA-7 human colon cancer cells publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2015.10.044 – volume: 4 start-page: 202 issue: 2 year: 2016 ident: 10.1016/j.prostaglandins.2019.106338_bib0235 article-title: Effect of oral Gabapentinon post-operative pain, morphine consumption, nausea and vomiting in patients with urgent appendectomy: a randomized double-blind placebo-controlled trial publication-title: Int. J. Adv. Biol. Biomed. Res. – volume: 69 start-page: 28 issue: Suppl 1(Suppl. 1) year: 2005 ident: 10.1016/j.prostaglandins.2019.106338_bib0075 article-title: Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2 publication-title: Oncology doi: 10.1159/000086629 – volume: 79 start-page: 95 issue: 1 year: 2006 ident: 10.1016/j.prostaglandins.2019.106338_bib0400 article-title: Prostaglandin E2 promotes degranulation‐independent release of MCP‐1 from mast cells publication-title: J. Leukoc. Biol. doi: 10.1189/jlb.0405226 – volume: 92 start-page: 660 issue: 6 year: 2010 ident: 10.1016/j.prostaglandins.2019.106338_bib0350 article-title: mPGES-1 as a target for cancer suppression: a comprehensive invited review “Phospholipase A2 and lipid mediators” publication-title: Biochimie doi: 10.1016/j.biochi.2010.02.006 – volume: 321 start-page: 187 issue: 2 year: 2012 ident: 10.1016/j.prostaglandins.2019.106338_bib0445 article-title: The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells publication-title: Cancer Lett. doi: 10.1016/j.canlet.2012.02.003 – year: 2019 ident: 10.1016/j.prostaglandins.2019.106338_bib0045 article-title: CD73 as a potential opportunity for cancer immunotherapy publication-title: Expert Opin. Ther. Targets doi: 10.1080/14728222.2019.1559829 – volume: 282 start-page: 11613 issue: 16 year: 2007 ident: 10.1016/j.prostaglandins.2019.106338_bib0375 article-title: Prostaglandin E receptors publication-title: J. Biol. Chem. doi: 10.1074/jbc.R600038200 – year: 2010 ident: 10.1016/j.prostaglandins.2019.106338_bib0505 article-title: PGE2 transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells publication-title: blood doi: 10.1182/blood-2009-12-258038 – volume: 18 start-page: 88 issue: 1 year: 2011 ident: 10.1016/j.prostaglandins.2019.106338_bib0560 article-title: Tazarotene-induced gene 1 inhibits prostaglandin E2-stimulated HCT116 colon cancer cell growth publication-title: J. Biomed. Sci. doi: 10.1186/1423-0127-18-88 – volume: 7 start-page: 3971 issue: 12 year: 2001 ident: 10.1016/j.prostaglandins.2019.106338_bib0160 article-title: Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer publication-title: Clin. Cancer Res. – volume: 352 start-page: 1092 issue: 11 year: 2005 ident: 10.1016/j.prostaglandins.2019.106338_bib0460 article-title: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa050493 – volume: 79 start-page: 191 issue: 2 year: 1999 ident: 10.1016/j.prostaglandins.2019.106338_bib0240 article-title: Tumour markers of prognosis in colorectal cancer publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6690033 – volume: 8 start-page: 289 issue: 3 year: 2002 ident: 10.1016/j.prostaglandins.2019.106338_bib0305 article-title: Prostaglandin E 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy publication-title: Nat. Med. doi: 10.1038/nm0302-289 – volume: 23 start-page: 1147 issue: 9 year: 2005 ident: 10.1016/j.prostaglandins.2019.106338_bib0280 article-title: Monoclonal antibody therapy of cancer publication-title: Nat. Biotechnol. doi: 10.1038/nbt1137 – volume: 15 start-page: 188 issue: 3 year: 2015 ident: 10.1016/j.prostaglandins.2019.106338_bib0440 article-title: Modulation by licofelone and celecoxib of experimentally induced cancer and preneoplastic lesions in mice exposed to cigarette smoke publication-title: Curr. Cancer Drug Targets doi: 10.2174/1568009615666150216170008 – volume: 27 start-page: 235 issue: 2 year: 2018 ident: 10.1016/j.prostaglandins.2019.106338_bib0020 article-title: Systemic therapy for colon cancer publication-title: Surg. Oncol. Clin. doi: 10.1016/j.soc.2017.11.001 – volume: 233 start-page: 2032 issue: 3 year: 2018 ident: 10.1016/j.prostaglandins.2019.106338_bib0030 article-title: Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer publication-title: J. Cell. Physiol. doi: 10.1002/jcp.25873 – volume: 278 start-page: 35451 issue: 37 year: 2003 ident: 10.1016/j.prostaglandins.2019.106338_bib0325 article-title: Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor publication-title: J. Biol. Chem. doi: 10.1074/jbc.M302474200 – volume: 246 start-page: 46 year: 2017 ident: 10.1016/j.prostaglandins.2019.106338_bib0050 article-title: CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice publication-title: J. Control. Release doi: 10.1016/j.jconrel.2016.12.012 – volume: 7 start-page: 1048 issue: 9 year: 2001 ident: 10.1016/j.prostaglandins.2019.106338_bib0115 article-title: Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc Δ716 knockout mice publication-title: Nat. Med. doi: 10.1038/nm0901-1048 – volume: 58 start-page: 239 year: 2007 ident: 10.1016/j.prostaglandins.2019.106338_bib0150 article-title: NSAIDs and cancer prevention: targets downstream of COX-2 publication-title: Annu. Rev. Med. doi: 10.1146/annurev.med.57.121304.131253 – volume: 24 start-page: 400 issue: 5 year: 2014 ident: 10.1016/j.prostaglandins.2019.106338_bib0165 article-title: Gastric cancer following bariatric surgery: a review publication-title: Surg. Laparosc. Endosc. Percutan. Tech. doi: 10.1097/SLE.0000000000000050 – volume: 34 start-page: 1349 issue: 3 year: 2013 ident: 10.1016/j.prostaglandins.2019.106338_bib0065 article-title: The role of natural killer T cells in B cell malignancies publication-title: Tumor Biol. doi: 10.1007/s13277-013-0743-x – volume: 6 start-page: 479 year: 2011 ident: 10.1016/j.prostaglandins.2019.106338_bib0220 article-title: Molecular genetics of colorectal cancer publication-title: Annu. Rev. Pathol. Mech. Dis. doi: 10.1146/annurev-pathol-011110-130235 – volume: 69 start-page: 145 issue: 1 year: 2000 ident: 10.1016/j.prostaglandins.2019.106338_bib0465 article-title: Cyclooxygenases: structural, cellular, and molecular biology publication-title: Ann. Rev. Biochem. doi: 10.1146/annurev.biochem.69.1.145 – volume: 336 start-page: 516 issue: 2 year: 2011 ident: 10.1016/j.prostaglandins.2019.106338_bib0540 article-title: The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin e2 on the proliferation of colon cancer cells publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.110.173278 – volume: 69 start-page: 730 issue: 12 year: 2011 ident: 10.1016/j.prostaglandins.2019.106338_bib0135 article-title: The Mediterranean diet: effects on proteins that mediate fatty acid metabolism in the colon publication-title: Nutr. Rev. doi: 10.1111/j.1753-4887.2011.00439.x – volume: 63 start-page: 5218 issue: 17 year: 2003 ident: 10.1016/j.prostaglandins.2019.106338_bib0520 article-title: Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin publication-title: Cancer Res. – volume: 68 start-page: 1192 issue: 7 year: 2016 ident: 10.1016/j.prostaglandins.2019.106338_bib0585 article-title: Colonic saturated fatty acid concentrations and expression of COX-1, but not diet, predict prostaglandin E2 in normal human colon tissue publication-title: Nutr. cancer Biol. doi: 10.1080/01635581.2016.1213866 – volume: 175 start-page: 1483 issue: 3 year: 2005 ident: 10.1016/j.prostaglandins.2019.106338_bib0420 article-title: Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells publication-title: J. Immunol. doi: 10.4049/jimmunol.175.3.1483 – volume: 116 start-page: 544 issue: 3 year: 2010 ident: 10.1016/j.prostaglandins.2019.106338_bib0215 article-title: Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates publication-title: Cancer: Interdiscip. Int. J. Am. Cancer Soc. doi: 10.1002/cncr.24760 – volume: 61 start-page: 135 issue: 1 year: 2012 ident: 10.1016/j.prostaglandins.2019.106338_bib0295 article-title: Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer publication-title: Gut doi: 10.1136/gut.2010.233718 – volume: 24 start-page: 225 issue: 2 year: 2014 ident: 10.1016/j.prostaglandins.2019.106338_bib0335 article-title: The role of leukotrienes in immunopathogenesis of rheumatoid arthritis publication-title: Mod. Rheumatol. doi: 10.3109/14397595.2013.854056 – volume: 66 start-page: 9794 issue: 20 year: 2006 ident: 10.1016/j.prostaglandins.2019.106338_bib0390 article-title: Targeting prostaglandin E EP receptors to inhibit metastasis publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-06-2067 – volume: 313 start-page: 2969 issue: 14 year: 2007 ident: 10.1016/j.prostaglandins.2019.106338_bib0530 article-title: The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells publication-title: Exp. Cell Res. doi: 10.1016/j.yexcr.2007.06.004 – volume: 9 start-page: 489 issue: 7 year: 2009 ident: 10.1016/j.prostaglandins.2019.106338_bib0025 article-title: Genetic prognostic and predictive markers in colorectal cancer publication-title: Nat. Rev. Cancer doi: 10.1038/nrc2645 – volume: 26 start-page: 525 issue: 3-4 year: 2007 ident: 10.1016/j.prostaglandins.2019.106338_bib0355 article-title: Cyclooxygenases, prostanoids, and tumor progression publication-title: Cancer Metastasis Rev. doi: 10.1007/s10555-007-9096-5 – volume: 203 start-page: 941 issue: 4 year: 2006 ident: 10.1016/j.prostaglandins.2019.106338_bib0120 article-title: CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer publication-title: J. Exp. Med. doi: 10.1084/jem.20052124 – volume: 352 start-page: 1071 issue: 11 year: 2005 ident: 10.1016/j.prostaglandins.2019.106338_bib0450 article-title: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa050405 – volume: 65 start-page: 1159 issue: 10 year: 2016 ident: 10.1016/j.prostaglandins.2019.106338_bib0040 article-title: Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-016-1879-5 – volume: 55 start-page: 3785 issue: 17 year: 1995 ident: 10.1016/j.prostaglandins.2019.106338_bib0085 article-title: Expression of cyclooxygenase-1 and-2 in human colorectal cancer publication-title: Cancer Res. – volume: 29 start-page: 33 year: 1999 ident: 10.1016/j.prostaglandins.2019.106338_bib0415 article-title: The paradigm of type 1 and type 2 antigen‐presenting cells. Implications for atopic allergy publication-title: Clin. Exp. Allergy doi: 10.1046/j.1365-2222.1999.00006.x-i2 – volume: 44 start-page: 381 issue: 1 year: 2016 ident: 10.1016/j.prostaglandins.2019.106338_bib0205 article-title: Application of liposomes in medicine and drug delivery publication-title: Artif. Cells Nanomed. Biotechnol. doi: 10.3109/21691401.2014.953633 – volume: 94 start-page: 3336 issue: 7 year: 1997 ident: 10.1016/j.prostaglandins.2019.106338_bib0330 article-title: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential publication-title: Proc. Natl. Acad. Sci. doi: 10.1073/pnas.94.7.3336 – volume: 361 start-page: 2449 issue: 25 year: 2009 ident: 10.1016/j.prostaglandins.2019.106338_bib0015 article-title: Molecular basis of colorectal cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra0804588 – volume: 342 start-page: 1946 issue: 26 year: 2000 ident: 10.1016/j.prostaglandins.2019.106338_bib0455 article-title: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis publication-title: N. Engl. J. Med. doi: 10.1056/NEJM200006293422603 – volume: 90 start-page: 1609 issue: 21 year: 1998 ident: 10.1016/j.prostaglandins.2019.106338_bib0130 article-title: Cyclooxygenase-2 inhibitors in tumorigenesis (Part II) publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/90.21.1609 – volume: 6 start-page: 40970 issue: 38 year: 2015 ident: 10.1016/j.prostaglandins.2019.106338_bib0290 article-title: Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin publication-title: Oncotarget doi: 10.18632/oncotarget.5403 – volume: 14 start-page: 1566 issue: 3 year: 2015 ident: 10.1016/j.prostaglandins.2019.106338_bib0525 article-title: Antagonist of prostaglandin E2 receptor 4 induces metabolic alterations in liver of mice publication-title: J. Proteome Res. doi: 10.1021/pr501236y – volume: 178 start-page: 4097 issue: 7 year: 2007 ident: 10.1016/j.prostaglandins.2019.106338_bib0475 article-title: Prostaglandin E2 induces the expression of IL-1α in colon cancer cells publication-title: J. Immunol. doi: 10.4049/jimmunol.178.7.4097 – volume: 67 start-page: 7 issue: 1 year: 2017 ident: 10.1016/j.prostaglandins.2019.106338_bib0270 article-title: Cancer statistics, 2017 publication-title: CA Cancer J. Clin. – volume: 76 start-page: 1 issue: 1 year: 2009 ident: 10.1016/j.prostaglandins.2019.106338_bib0230 article-title: Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications publication-title: Clin. Genet. doi: 10.1111/j.1399-0004.2009.01230.x – volume: 19 start-page: 619 issue: 5 year: 2013 ident: 10.1016/j.prostaglandins.2019.106338_bib0250 article-title: A colorectal cancer classification system that associates cellular phenotype and responses to therapy publication-title: Nat. Med. doi: 10.1038/nm.3175 – volume: 152 start-page: 217 issue: 2 year: 2000 ident: 10.1016/j.prostaglandins.2019.106338_bib0510 article-title: Effect of prostaglandin E2 on the proliferation, Ca2+ mobilization and cAMP in HT-29 human colon adenocarcinoma cells publication-title: Cancer Lett. doi: 10.1016/S0304-3835(00)00339-6 – volume: 487 start-page: 330 issue: 7407 year: 2012 ident: 10.1016/j.prostaglandins.2019.106338_bib0005 article-title: Comprehensive molecular characterization of human colon and rectal cancer publication-title: Nature doi: 10.1038/nature11252 – volume: 11 start-page: 252 issue: 2 year: 2007 ident: 10.1016/j.prostaglandins.2019.106338_bib0365 article-title: Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin–proteasome system and Cox‐2 publication-title: J. Cell. Mol. Med. doi: 10.1111/j.1582-4934.2007.00032.x – volume: 59 start-page: 5093 issue: 20 year: 1999 ident: 10.1016/j.prostaglandins.2019.106338_bib0125 article-title: Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis publication-title: Cancer Res. – volume: 161 start-page: 3746 issue: 7 year: 1998 ident: 10.1016/j.prostaglandins.2019.106338_bib0405 article-title: Prostaglandin E2 stimulates IL-8 gene expression in human colonic epithelial cells by a posttranscriptional mechanism publication-title: J. Immunol. doi: 10.4049/jimmunol.161.7.3746 – volume: 718 start-page: 408 issue: 1-3 year: 2013 ident: 10.1016/j.prostaglandins.2019.106338_bib0490 article-title: Induction of cyclooxygenase-2 expression by prostaglandin E2 stimulation of the prostanoid EP4 receptor via coupling to Gαi and transactivation of the epidermal growth factor receptor in HCA-7 human colon cancer cells publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2013.08.002 – volume: 99 start-page: 2254 issue: 9 year: 1997 ident: 10.1016/j.prostaglandins.2019.106338_bib0090 article-title: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2 publication-title: J. Clin. Invest. doi: 10.1172/JCI119400 – volume: 8 start-page: 58 issue: 1 year: 2013 ident: 10.1016/j.prostaglandins.2019.106338_bib0285 article-title: Systems intervention to promote colon cancer screening in safety net settings: protocol for a community-based participatory randomized controlled trial publication-title: Implement. Sci. doi: 10.1186/1748-5908-8-58 – volume: 18 start-page: 61 issue: 1 year: 2011 ident: 10.1016/j.prostaglandins.2019.106338_bib0555 article-title: JNK suppression is essential for 17β-Estradiol inhibits prostaglandin E2-Induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells publication-title: J. Biomed. Sci. doi: 10.1186/1423-0127-18-61 – volume: 165 start-page: 4298 issue: 8 year: 2000 ident: 10.1016/j.prostaglandins.2019.106338_bib0410 article-title: Autoregulation of human monocyte-derived dendritic cell maturation and IL-12 production by cyclooxygenase-2-mediated prostanoid production publication-title: J. Immunol. doi: 10.4049/jimmunol.165.8.4298 – volume: 336 start-page: 516 issue: 2 year: 2011 ident: 10.1016/j.prostaglandins.2019.106338_bib0545 article-title: The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin E2 on the proliferation of colon cancer cells publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.110.173278 – year: 2001 ident: 10.1016/j.prostaglandins.2019.106338_bib0105 article-title: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells publication-title: J. Biol. Chem. doi: 10.1074/jbc.M009689200 – volume: 83 start-page: 324 issue: 3 year: 2000 ident: 10.1016/j.prostaglandins.2019.106338_bib0110 article-title: Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer publication-title: Br. J. Cancer doi: 10.1054/bjoc.2000.1270 – volume: 77 start-page: 480 issue: Suppl 2 year: 2015 ident: 10.1016/j.prostaglandins.2019.106338_bib0565 article-title: Fine-needle aspiration, touch imprint, and crush preparation cytology for diagnosing thyroid malignancies in thyroid nodules publication-title: Indian J. Surg. doi: 10.1007/s12262-013-0882-8 – volume: 34 start-page: 2031 issue: 4 year: 2013 ident: 10.1016/j.prostaglandins.2019.106338_bib0055 article-title: Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions publication-title: Tumor Biol. doi: 10.1007/s13277-013-0832-x – volume: 280 start-page: 26565 issue: 28 year: 2005 ident: 10.1016/j.prostaglandins.2019.106338_bib0495 article-title: Prostaglandin E2 stimulates the β-catenin/T cell factor-dependent transcription in colon cancer publication-title: J. Biol. Chem. doi: 10.1074/jbc.M413056200 – volume: 18 start-page: 1132 issue: 6 year: 2017 ident: 10.1016/j.prostaglandins.2019.106338_bib0575 article-title: Prostaglandin E2-induced COX-2 expressions via EP2 and EP4 signaling pathways in human LoVo colon cancer cells publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms18061132 – volume: 336 start-page: 516 issue: 2 year: 2011 ident: 10.1016/j.prostaglandins.2019.106338_bib0070 article-title: The effects of the stromal cell-derived cyclooxygenase-2 metabolite prostaglandin E2 on the proliferation of colon cancer cells publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.110.173278 – volume: 42 start-page: 198 issue: 2 year: 2010 ident: 10.1016/j.prostaglandins.2019.106338_bib0380 article-title: Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances publication-title: Int. J. Biochem. Cell Biol. doi: 10.1016/j.biocel.2009.09.015 – volume: 348 start-page: 919 issue: 10 year: 2003 ident: 10.1016/j.prostaglandins.2019.106338_bib0255 article-title: Hereditary colorectal cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra012242 – volume: 32 start-page: 219 issue: 2 year: 2010 ident: 10.1016/j.prostaglandins.2019.106338_bib0340 article-title: Immunopharmacological role of the leukotriene receptor antagonists and inhibitors of leukotrienes generating enzymes in multiple sclerosis publication-title: Immunopharmacol. Immunotoxicol. doi: 10.3109/08923970903283662 – year: 2010 ident: 10.1016/j.prostaglandins.2019.106338_bib0345 article-title: Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-0788 – volume: 11 start-page: 307 issue: 1 year: 2016 ident: 10.1016/j.prostaglandins.2019.106338_bib0195 article-title: New updates pertaining to drug delivery of local anesthetics in particular bupivacaine using lipid nanoparticles publication-title: Nanoscale Res. Lett. doi: 10.1186/s11671-016-1520-8 – volume: 112 start-page: 3167 issue: 11 year: 2011 ident: 10.1016/j.prostaglandins.2019.106338_bib0535 article-title: Protein kinase CK2 promotes cancer cell viability via up‐regulation of cyclooxygenase‐2 expression and enhanced prostaglandin E2 production publication-title: J. Cell. Biochem. doi: 10.1002/jcb.23247 – volume: 93 start-page: 681 issue: 5 year: 2001 ident: 10.1016/j.prostaglandins.2019.106338_bib0360 article-title: Increased cyclooxygenase‐2 (cox‐2) expression and activity in a murine model of metastatic breast cancer publication-title: Int. J. Cancer doi: 10.1002/ijc.1397 – volume: 99 start-page: 2254 issue: 9 year: 1997 ident: 10.1016/j.prostaglandins.2019.106338_bib0315 article-title: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2 publication-title: J. Clin. Invest. doi: 10.1172/JCI119400 – volume: 64 start-page: 9 issue: 1 year: 2014 ident: 10.1016/j.prostaglandins.2019.106338_bib0010 article-title: Cancer statistics, 2014 publication-title: CA Cancer J. Clin. – start-page: 1975 year: 2006 ident: 10.1016/j.prostaglandins.2019.106338_bib0170 – volume: 4 start-page: 42 issue: 1 year: 2014 ident: 10.1016/j.prostaglandins.2019.106338_bib0210 article-title: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-13-0315 – volume: 10 start-page: 1056 issue: 10 year: 2010 ident: 10.1016/j.prostaglandins.2019.106338_bib0485 article-title: The induction of S100p expression by the Prostaglandin E2 (PGE2)/EP4 receptor signaling pathway in colon cancer cells publication-title: Cancer Biol. Ther. doi: 10.4161/cbt.10.10.13373 – volume: 181 start-page: 721 issue: 1 year: 2008 ident: 10.1016/j.prostaglandins.2019.106338_bib0425 article-title: In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells publication-title: J. Immunol. doi: 10.4049/jimmunol.181.1.721 – volume: 32 start-page: 543 issue: 4 year: 2010 ident: 10.1016/j.prostaglandins.2019.106338_bib0435 article-title: Prostaglandins in pathogenesis and treatment of multiple sclerosis publication-title: Immunopharmacol. Immunotoxicol. doi: 10.3109/08923971003667627 – volume: 7 start-page: 147 issue: 3 year: 2017 ident: 10.1016/j.prostaglandins.2019.106338_bib0175 article-title: Berries and other natural products in pancreatic cancer chemoprevention in human clinical trials publication-title: J. Berry Res. doi: 10.3233/JBR-170159 – volume: 310 start-page: 1504 issue: 5753 year: 2005 ident: 10.1016/j.prostaglandins.2019.106338_bib0095 article-title: Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-ß-catenin signaling axis publication-title: Science doi: 10.1126/science.1116221 – volume: 4 start-page: 431 issue: 6 year: 2003 ident: 10.1016/j.prostaglandins.2019.106338_bib0385 article-title: Targeting cyclooxygenase-2 in human neoplasia: rationale and promise publication-title: Cancer Cell doi: 10.1016/S1535-6108(03)00310-6 – volume: 65 start-page: 853 issue: 16 year: 2016 ident: 10.1016/j.prostaglandins.2019.106338_bib0190 article-title: Albumin-based biomaterial for lung tissue engineering applications publication-title: Int. J. Polym. Mater. Polym. Biomater. doi: 10.1080/00914037.2016.1180610 – volume: 12 start-page: 2375 issue: 19 year: 2006 ident: 10.1016/j.prostaglandins.2019.106338_bib0300 article-title: Roles of prostanoids in colon carcinogenesis and their potential targeting for cancer chemoprevention publication-title: Curr. Pharm. Des. doi: 10.2174/138161206777698972 – volume: 23 start-page: 1171 issue: 7 year: 2017 ident: 10.1016/j.prostaglandins.2019.106338_bib0580 article-title: Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v23.i7.1171 – volume: 99 start-page: 502 issue: 3 year: 2008 ident: 10.1016/j.prostaglandins.2019.106338_bib0500 article-title: Prostaglandin E 2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6604490 – volume: 29 start-page: 781 issue: 6 year: 2010 ident: 10.1016/j.prostaglandins.2019.106338_bib0155 article-title: The role of COX-2 in intestinal inflammation and colorectal cancer publication-title: Oncogene doi: 10.1038/onc.2009.421 – volume: 34 start-page: e00161 issue: 6 year: 2014 ident: 10.1016/j.prostaglandins.2019.106338_bib0275 article-title: Lentivirus-mediated knockdown of eukaryotic translation initiation factor 3 subunit D inhibits proliferation of HCT116 colon cancer cells publication-title: Biosci. Rep. doi: 10.1042/BSR20140078 – year: 2011 ident: 10.1016/j.prostaglandins.2019.106338_bib0430 article-title: Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells towards stable myeloid-derived suppressor cells publication-title: Blood doi: 10.1182/blood-2011-07-365825 – volume: 5 start-page: 845 issue: 11 year: 2005 ident: 10.1016/j.prostaglandins.2019.106338_bib0245 article-title: Biomarkers in cancer staging, prognosis and treatment selection publication-title: Nat. Rev. Cancer doi: 10.1038/nrc1739 – volume: 44 start-page: 410 issue: 1 year: 2016 ident: 10.1016/j.prostaglandins.2019.106338_bib0200 article-title: Application of gold nanoparticles in biomedical and drug delivery publication-title: Artif. Cells Nanomed. Biotechnol. doi: 10.3109/21691401.2014.955107 – volume: 111 start-page: 5821 issue: 10 year: 2011 ident: 10.1016/j.prostaglandins.2019.106338_bib0145 article-title: Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis publication-title: Chem. Rev. doi: 10.1021/cr2002992 – volume: 47 year: 2011 ident: 10.1016/j.prostaglandins.2019.106338_bib0265 article-title: Current standards and new trends in the primary treatment of colorectal cancer publication-title: Eur. J. Cancer doi: 10.1016/S0959-8049(11)70183-6 – volume: 260 start-page: 812 issue: 5109 year: 1993 ident: 10.1016/j.prostaglandins.2019.106338_bib0180 article-title: Clues to the pathogenesis of familial colorectal cancer publication-title: Science doi: 10.1126/science.8484121 – volume: 342 start-page: 63 issue: 1-2 year: 2010 ident: 10.1016/j.prostaglandins.2019.106338_bib0550 article-title: 17β-Estradiol inhibits prostaglandin E2-induced COX-2 expressions and cell migration by suppressing Akt and ERK1/2 signaling pathways in human LoVo colon cancer cells publication-title: Mol. Cell. Biochem. doi: 10.1007/s11010-010-0469-7 – volume: 8 start-page: 289 issue: 3 year: 2002 ident: 10.1016/j.prostaglandins.2019.106338_bib0595 article-title: Prostaglandin E 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy publication-title: Nat. Med. doi: 10.1038/nm0302-289 – volume: 2 start-page: 258 issue: 109 year: 1997 ident: 10.1016/j.prostaglandins.2019.106338_bib0395 article-title: Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under FCS-free conditions: effect of culture conditions on the type of T cell response publication-title: J. Invest. Dermatol. – volume: 108 start-page: 1415 year: 2018 ident: 10.1016/j.prostaglandins.2019.106338_bib0035 article-title: The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2018.09.177 – volume: 276 start-page: 18075 issue: 21 year: 2001 ident: 10.1016/j.prostaglandins.2019.106338_bib0320 article-title: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells publication-title: J. Biol. Chem. doi: 10.1074/jbc.M009689200 – volume: 436 start-page: 792 issue: 7052 year: 2005 ident: 10.1016/j.prostaglandins.2019.106338_bib0185 article-title: Colorectal cancer: mutations in a signalling pathway publication-title: Nature doi: 10.1038/436792a – volume: 10 start-page: 353 issue: 6 year: 2009 ident: 10.1016/j.prostaglandins.2019.106338_bib0225 article-title: New insights into the aetiology of colorectal cancer from genome-wide association studies publication-title: Nat. Rev. Genet. doi: 10.1038/nrg2574 – volume: 36 start-page: 7339 issue: 10 year: 2015 ident: 10.1016/j.prostaglandins.2019.106338_bib0060 article-title: Myeloid-derived suppressor cells in B cell malignancies publication-title: Tumor Biol. doi: 10.1007/s13277-015-4004-z – volume: 44 start-page: 769 issue: 3 year: 2016 ident: 10.1016/j.prostaglandins.2019.106338_bib0590 article-title: Immunotherapeutic approaches for cancer therapy: an updated review publication-title: Artif. Cells Nanomed. Biotechnol. – volume: 1 start-page: 11 issue: 1 year: 2001 ident: 10.1016/j.prostaglandins.2019.106338_bib0260 article-title: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 publication-title: Nat. Rev. Cancer doi: 10.1038/35094017 – volume: 107 start-page: 1183 issue: 4 year: 1994 ident: 10.1016/j.prostaglandins.2019.106338_bib0080 article-title: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas publication-title: Gastroenterology doi: 10.1016/0016-5085(94)90246-1 – volume: 69 start-page: 28 issue: Suppl. 1 year: 2005 ident: 10.1016/j.prostaglandins.2019.106338_bib0140 article-title: Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2 publication-title: Oncology doi: 10.1159/000086629 – volume: 117 start-page: 223 issue: 2 year: 2004 ident: 10.1016/j.prostaglandins.2019.106338_bib0515 article-title: Levamisole modulates prostaglandin E2 production and cyclooxygenase II gene expression in human colonic cancer cells1 publication-title: J. Surg. Res. doi: 10.1016/j.jss.2003.11.010 |
| SSID | ssj0020110 |
| Score | 2.5295486 |
| SecondaryResourceType | review_article |
| Snippet | •Colon cancer in one of the main health-related problems which is incurable particularly in advanced stages.•Prostanoids and particularly prostaglandin E2... Although colon cancer is one of the most important triggers of cancer related mortality, a few therapeutic options exist for this disease, including... |
| SourceID | swepub proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 106338 |
| SubjectTerms | Colon cancer Colonic Neoplasms - drug therapy Colonic Neoplasms - metabolism Colonic Neoplasms - pathology Cyclooxygenase-2 Dinoprostone - metabolism E-type prostanoid receptor Humans Molecular Targeted Therapy - methods Prostaglandin E2 |
| Title | Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer |
| URI | https://dx.doi.org/10.1016/j.prostaglandins.2019.106338 https://www.ncbi.nlm.nih.gov/pubmed/31100474 https://www.proquest.com/docview/2232038793 http://kipublications.ki.se/Default.aspx?queryparsed=id:142251617 |
| Volume | 144 |
| WOSCitedRecordID | wos000494887500013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 issn: 1098-8823 databaseCode: AIEXJ dateStart: 19980101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.sciencedirect.com omitProxy: false ssIdentifier: ssj0020110 providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6DiFeEDA-ysdkpG0vVVATu3UsHlAFrQB1ZQ8d6ltkOwn9TELbTeMf4O_mbCdpyjSpPPASRW7spL5fnDvf7-4QOvFCCXqykA4RXDnU9VxHupI7shVy1VYtyYgJFB6w4dAfj_lFrfa7iIW5XrAk8W9uePZfRQ1tIGwdOvsP4i4HhQY4B6HDEcQOx70Ef6HjOIQpzTFNmj1PV5IRzSzdaK9_JdyqaUnglmdY0s0Ny3wBkFAaDquq7roz8NpgxoRvNRfTbBraGBRdu6dcw8Uq04x7s3HzXUwK7rx2gsznk9QG2MR6D6wEVzqbiY3TB2tbJD8M0eA8nYjlUmz7imVoSeGVrvm2hctLAlyx0upEpqDek52lmNLKYgrWKrGpX26t83bLYaa_MpV_rpl6_N2222567eG3oH85GASj3nh0SvrZT0fXHtM--lPyyeLgAB16rM39OjrsfumNv5amu9aSjN88f-j76GTLFLz7Ie5Sdm4bM39lqjXazegRepibJbhr4fQY1aLkCTrqJiDQ5S98hg1R2HhgjtD5DhBwz8NijQW2CMMVhGGLMAwIwyXCcBpjgzBsEfYUXfZ7o4-fnbwqh6Mob210RlERcl0VgbJYdaRkfiw83_eVH2kSAyGKwgvOGQ_bsu2GoBvFrhRurODT0Qoj8gzVkzSJXiCsr5EuNCkuqCsoDME7TCnQ6iXhpNNA74vpC1Sesl5XTlkEBTdxFuxOfqAnP7CT30DtsndmU7fs2e9DIakgV0OtehkA-vYc4W0h4ABWa-2CE0mUXsFFYMBowggnDfTcSr58NmKyNzLaQGcWCuUvOgV83jSHsyigjDNKX-5xm1fowfbte43qm9VV9AbdU9eb6Xp1jA7Y2D_Owf4HdczTvw |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prostaglandin+E2+as+a+potent+therapeutic+target+for+treatment+of+colon+cancer&rft.jtitle=Prostaglandins+%26+other+lipid+mediators&rft.au=Karpisheh%2C+Vahid&rft.au=Nikkhoo%2C+Afshin&rft.au=Hojjat-Farsangi%2C+Mohammad&rft.au=Namdar%2C+Afshin&rft.date=2019-10-01&rft.issn=1098-8823&rft.volume=144&rft.spage=106338&rft_id=info:doi/10.1016%2Fj.prostaglandins.2019.106338&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-8823&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-8823&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-8823&client=summon |